Movement Alert｜Twist Bioscience Corp Falls 5.51% in Regular Trading, Earlier Rating Initiations and Lilly Collaboration Continue to Be Digested

Market Focus11-02 23:09

On November 2, Twist Bioscience Corp fell 5.51% in regular trading, trading at $145.03 per share, with turnover of $42.15 million.

Publicly available information indicates the market is still digesting earlier brokerage coverage and the company’s collaboration with Eli Lilly’s TuneLab platform, while no stronger new catalyst has been disclosed alongside the move.

Background developments show Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 price target. Separately, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly, with the collaboration focused on antibody drug discovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment